News
July 29, 2025
FDA Approves Pegcetacoplan (Empaveli) for C3 Glomerulopathy, IC-MPGN
The FDA has approved pegcetacoplan as the first treatment for C3G and primary IC-MPGN in patients aged ≥12.
The FDA has approved pegcetacoplan as the first treatment for C3G and primary IC-MPGN in patients aged ≥12.
Premium Content
This article is available to subscribers only. Subscribe to read the full article.
Category:
Politics